Glaukos Corporation Plans Financial Results Announcement
Glaukos Corporation (NYSE: GKOS), known for its focus on innovative therapies in ophthalmic pharmaceuticals and medical technology, is getting ready to unveil its financial performance for the fourth quarter and full year 2024. The announcement is scheduled to occur after the market closes on February 20, 2025. Subsequently, Glaukos management will host a conference call along with a live webcast to discuss these results at 1:30 p.m. PT (4:30 p.m. ET) on the same day.
Details of the Upcoming Webcast
Investors and interested parties can find a link to the webcast on Glaukos’ official website. Those wishing to join the conference call can dial in using the following numbers: 888-210-2212 for U.S. participants or 646-960-0390 for international callers. Remember to enter the Conference ID 7935742. A replay of the call will also be made available on Glaukos' site once the live session concludes.
Innovation at Glaukos
Founded on a commitment to addressing serious eye health issues, Glaukos has pioneered the field of Micro-Invasive Glaucoma Surgery (MIGS). They launched their first device in the MIGS category back in 2012, revolutionizing treatment approaches for glaucoma patients. In an exciting development for 2024, Glaukos has initiated commercial activities for iDose TR, an innovative, long-duration drug delivery system designed specifically to manage glaucoma therapy directly within the eye.
iDose TR: A Breakthrough in Glaucoma Treatment
The iDose TR represents a significant milestone in managing glaucoma as it offers 24/7 drug delivery directly into the eye over extended periods, enhancing patient compliance and therapeutic effectiveness. This advancement reflects Glaukos' ongoing commitment to improving patient outcomes in ophthalmic care.
FDA-Approved Therapies and Future Prospects
Moreover, Glaukos has successfully introduced the first FDA-approved corneal cross-linking treatment using a unique bio-activated pharmaceutical. This therapy plays a crucial role in addressing keratoconus, a rare corneal disease. Glaukos remains dedicated to driving advancements in eye care, with a robust pipeline of innovative technologies focused on enhancing treatment standards for chronic eye conditions.
About Glaukos Corporation
Glaukos Corporation specializes in the development and commercialization of state-of-the-art therapies for various eye diseases including glaucoma and corneal disorders. Their focus on research and innovation establishes them as leaders in the ophthalmic sector, continually striving to elevate the standard of care for patients globally.
Frequently Asked Questions
What financial results is Glaukos expected to announce?
Glaukos will be releasing its financial results for the fourth quarter and full year 2024.
When will Glaukos hold the conference call?
The conference call will take place on February 20, 2025, at 1:30 p.m. PT (4:30 p.m. ET).
How can I access the webcast for the financial results?
A link to the live webcast will be available on Glaukos’ official website ahead of the call.
What is iDose TR?
iDose TR is a long-duration drug delivery system designed to provide continuous glaucoma therapy directly in the eye.
What therapies do Glaukos offer?
Glaukos provides innovative treatments for glaucoma, corneal disorders, and retinal diseases, including FDA-approved drugs and procedural technologies.
